Skip to main content

Veradermics, Inc 10-Q for FY2026 Q3

Veradermics, Inc (MANE)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Veradermics, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Veradermics reported positive Study ‘304’ Phase 3 results for VDPHL01 in male pattern hair loss. Nine-month net loss was $71.7 million, while $798.4 million of cash, cash equivalents and marketable securities was expected to fund operations into 2030. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$21M
compared with a net loss of $20.1M a year earlier
Diluted EPS
-$0.50
compared with -$30.15 a year earlier